Effects of BIONESS in Rehabilitation of Stroke (EFES-BIO-SEP)
Primary Purpose
Stroke
Status
Completed
Phase
Not Applicable
Locations
Germany
Study Type
Interventional
Intervention
Bioness-300
Sponsored by

About this trial
This is an interventional treatment trial for Stroke
Eligibility Criteria
Inclusion Criteria:
- Adults between the ages of 18 and 75
- Inadequate ankle dorsiflexion during the swing phase of gait, resulting in inadequate limb clearance
- Medically stable for at least one week following the last episode of stroke
- Stable medication for four weeks
- Adequate cognitive and communication function to give informed consent, understand the training instructions, use the device, and give adequate feedback
- Ability to walk with or without an assistive device (except parallel bars) at least 10 meters
Exclusion Criteria:
• Lower motor neuron injury with inadequate response to stimulation
- History of falls greater than once a week
- Severe cardiac disease such as myocardial infarction, congestive heart failure, or a demand pacemaker
- Patients who have other electrical stimulation devices implemented
- Patients with epilepsy and with autoimmune diseases
Sites / Locations
- Neurological Clinic Medicalpark Bad Feilnbach
Arms of the Study
Arm 1
Arm Type
Other
Arm Label
Open labele BIONESS-Training
Arm Description
Four-week therapeutic treatment of foot drop with the electrical stimulation device Bioness L300. This treatment will be performed five times a week for at least 30 minutes
Outcomes
Primary Outcome Measures
SEP measurement
in improving pathological latencies and / or amplitudes of somatosensory evoked potentials (SEPs)
• N35, P40, N50 (lower limb / tibial nerve) amplitude of somatosensory evoked potential [ Time Frame: Change from baseline at 4 weeks]
Secondary Outcome Measures
Motor score improvement
• Dorsal flexion/plantar extension of the ankle strength will be measured by Janda's classification of muscle imbalance patterns (Force produced by voluntary dorsiflexion). [ Time Frame: Change from baseline at 4 weeks]
Full Information
NCT ID
NCT04767360
First Posted
February 17, 2021
Last Updated
March 14, 2023
Sponsor
LMU Klinikum
Collaborators
Peter Young Neurological Clinic Medicalpark Bad Feilnbach, Germany
1. Study Identification
Unique Protocol Identification Number
NCT04767360
Brief Title
Effects of BIONESS in Rehabilitation of Stroke
Acronym
EFES-BIO-SEP
Official Title
Short-term Therapeutic Effects of Functional Electrical Stimulation Device Bioness L300 on the Somatosensory Cortical Representation in the Rehabilitation of Patients After Stroke
Study Type
Interventional
2. Study Status
Record Verification Date
March 2023
Overall Recruitment Status
Completed
Study Start Date
February 10, 2021 (Actual)
Primary Completion Date
October 19, 2021 (Actual)
Study Completion Date
December 12, 2022 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
LMU Klinikum
Collaborators
Peter Young Neurological Clinic Medicalpark Bad Feilnbach, Germany
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
5. Study Description
Brief Summary
A four-weeks randomized clinical two-period crossover-design study will be conducted. Each patient will be randomized in a two separate consecutive treatment periods (Parallel Group Design). "Group A" will be treated with functional electrical stimulation (FES) and a second "Gruppe B" will be treated without FES for two weeks. After this period Group A and Group B will switched.
Detailed Description
Prediction of motor recovery in the upper-limb (UL) / lower-limb (LL) in patients with stroke is generally based on clinical examination. However, according to former studies neurophysiological measures may also have a predictive value. In the acute phase, the combination of the motor score and SEPs are best predictive of outcome. Neurophysiological measures alone are of limited value in predicting long term outcome. However, predictive accuracy is substantially improved through the combined use of both of these measures and clinical variables.
A four-weeks randomized clinical two-period crossover-design study will be conducted. Each patient will be randomized in a two separate consecutive treatment periods (Parallel Group Design). "Group A" will be treated with functional electrical stimulation (FES) and a second "Gruppe B" will be treated without FES for two weeks. After this period Group A and Group B will switched.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Stroke
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Sequential Assignment
Model Description
clinical sequential two-period crossover-design study
Masking
None (Open Label)
Allocation
N/A
Enrollment
32 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Open labele BIONESS-Training
Arm Type
Other
Arm Description
Four-week therapeutic treatment of foot drop with the electrical stimulation device Bioness L300. This treatment will be performed five times a week for at least 30 minutes
Intervention Type
Device
Intervention Name(s)
Bioness-300
Intervention Description
Therapeutic treatment of foot drop with the electrical stimulation device Bioness L300.
Primary Outcome Measure Information:
Title
SEP measurement
Description
in improving pathological latencies and / or amplitudes of somatosensory evoked potentials (SEPs)
• N35, P40, N50 (lower limb / tibial nerve) amplitude of somatosensory evoked potential [ Time Frame: Change from baseline at 4 weeks]
Time Frame
4 weeks
Secondary Outcome Measure Information:
Title
Motor score improvement
Description
• Dorsal flexion/plantar extension of the ankle strength will be measured by Janda's classification of muscle imbalance patterns (Force produced by voluntary dorsiflexion). [ Time Frame: Change from baseline at 4 weeks]
Time Frame
4 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Adults between the ages of 18 and 75
Inadequate ankle dorsiflexion during the swing phase of gait, resulting in inadequate limb clearance
Medically stable for at least one week following the last episode of stroke
Stable medication for four weeks
Adequate cognitive and communication function to give informed consent, understand the training instructions, use the device, and give adequate feedback
Ability to walk with or without an assistive device (except parallel bars) at least 10 meters
Exclusion Criteria:
• Lower motor neuron injury with inadequate response to stimulation
History of falls greater than once a week
Severe cardiac disease such as myocardial infarction, congestive heart failure, or a demand pacemaker
Patients who have other electrical stimulation devices implemented
Patients with epilepsy and with autoimmune diseases
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Benedikt Schoser, MD
Organizational Affiliation
Friedrich-Baur-Institute, Dep. of Neurology LMU Klinikum Munich Germany
Official's Role
Principal Investigator
Facility Information:
Facility Name
Neurological Clinic Medicalpark Bad Feilnbach
City
Bad Feilnbach
State/Province
Bavaria
ZIP/Postal Code
83075
Country
Germany
12. IPD Sharing Statement
Plan to Share IPD
No
Links:
URL
http://www.medicalpark.de
Description
homepage Medicalpark Clinics
Learn more about this trial
Effects of BIONESS in Rehabilitation of Stroke
We'll reach out to this number within 24 hrs